Table 1.
Patient cohort and univariable analysis.
| No TILs N=171 (16.8%) | TILs N=846 (83.2%) | nbTILs N=759 (74.6%) | bTILs N=87 (8.6%) | ||
|---|---|---|---|---|---|
| N (%) | N (%) | N (%) | N (%) | p-value* | |
| Age, years, median (IQR) | 60 (49–68) | 62 (53–71) | 62 (53–71) | 60 (49–72) | 0.04 |
| Sex | |||||
| Male | 106 (62.0) | 521 (61.6) | 462 (60.9) | 59 (67.8) | 0.92 |
| Female | 65 (38.0) | 325 (38.4) | 297 (39.1) | 28 (32.2) | |
| Race | |||||
| White | 149 (87.1) | 751 (88.8) | 674 (88.8) | 77 (88.5) | 0.15 |
| Black | 6 (3.5) | 12 (1.4) | 11 (1.5) | 1 (1.2) | |
| AAPI | 9 (5.3) | 32 (3.8) | 28 (3.7) | 4 (4.6) | |
| Not reported | 7 (4.1) | 51 (6.0) | 46 (6.1) | 5 (5.8) | |
| Location | |||||
| Head/neck | 24 (14.0) | 103 (12.2) | 95 (12.5) | 8 (9.2) | 0.01 |
| Extremity | 103 (60.2) | 419 (49.5) | 385 (50.7) | 34 (39.1) | |
| Trunk | 44 (25.7) | 324 (38.3) | 279 (36.8) | 45 (51.7) | |
| Histology | |||||
| Superficial spreading | 66 (38.6) | 418 (49.4) | 370 (48.8) | 48 (55.2) | <0.01 |
| Nodular | 46 (26.9) | 267 (31.6) | 246 (32.4) | 21 (24.1) | |
| Lentigo maligna | 8 (4.7) | 43 (5.1) | 40 (5.3) | 3 (3.5) | |
| Acral lentiginous | 19 (11.1) | 23 (2.7) | 19 (2.5) | 4 (4.6) | |
| NOS | 32 (18.7) | 95 (11.2) | 84 (11.1) | 11 (12.6) | |
| Thickness, mm, median (IQR) | 2.0 (1.2–3.4) | 1.9 (1.3–3.0) | 1.9 (1.3–3.2) | 1.5 (1.1–2.2) | 0.32 |
| Ulceration | |||||
| Absent | 126 (73.7) | 576 (68.1) | 514 (67.7) | 62 (71.3) | 0.34 |
| Present | 43 (25.2) | 255 (30.1) | 232 (30.6) | 23 (26.4) | |
| Unknown | 2 (1.2) | 15 (1.8) | 13 (1.7) | 2 (2.3) | |
| Mitotic count/mm2, median (IQR) | 3.4 (1.3–7.7) | 4.0 (1.2–8.0) | 4.0 (1.5–8.0) | 3.3 (1.0–6.0) | 0.74 |
| Regression | |||||
| Absent | 136 (79.5) | 613 (72.5) | 564 (74.3) | 49 (56.3) | <0.01 |
| Present | 21 (12.3) | 200 (23.6) | 164 (21.6) | 36 (41.4) | |
| Unknown | 14 (8.2) | 33 (3.9) | 31 (4.1) | 2 (2.3) | |
| Vertical growth phase | |||||
| Absent | 40 (23.4) | 213 (25.2) | 190 (25.0) | 23 (26.4) | 0.62 |
| Present | 127 (74.3) | 621 (73.4) | 560 (73.8) | 61 (70.1) | |
| Unknown | 4 (2.3) | 12 (1.4) | 9 (1.2) | 3 (3.5) | |
| Lymphovascular invasion | |||||
| Absent | 132 (77.2) | 739 (87.4) | 656 (86.4) | 83 (95.4) | <0.01 |
| Present | 26 (15.2) | 80 (9.5) | 76 (10.0) | 4 (4.6) | |
| Unknown | 13 (7.6) | 27 (3.2) | 27 (3.6) | 0 (0.0) | |
| Neurotropism | |||||
| Absent | 99 (57.9) | 552 (65.3) | 493 (65.0) | 59 (67.8) | 0.19 |
| Present | 10 (5.9) | 39 (4.6) | 37 (4.9) | 2 (2.3) | |
| Unknown | 62 (36.3) | 255 (30.1) | 229 (30.2) | 26 (29.9) | |
| Microsatellitosis | |||||
| Absent | 145 (84.8) | 746 (88.2) | 664 (87.5) | 82 (94.3) | 0.07 |
| Present | 11 (6.4) | 62 (7.3) | 60 (7.9) | 2 (2.3) | |
| Unknown | 15 (8.8) | 38 (4.5) | 35 (4.6) | 3 (3.5) | |
| Sentinel lymph node status | |||||
| Negative | 129 (75.4) | 710 (83.9) | 630 (83.0) | 80 (92.0) | <0.01 |
| Positive | 42 (24.6) | 136 (16.1) | 129 (17.0) | 7 (8.1) | |
| Completion lymph node dissection | |||||
| No | 160 (93.6) | 789 (93.3) | 704 (92.8) | 85 (97.7) | 0.88 |
| Yes | 11 (6.4) | 57 (6.7) | 55 (7.3) | 2 (2.3) | |
| Adjuvant therapy | |||||
| No | 160 (93.6) | 810 (95.7) | 725 (95.5) | 85 (97.7) | 0.22 |
| Yes | 11 (6.4) | 36 (4.3) | 34 (4.5) | 2 (2.3) | |
| Interferon | 7 (63.6) | 11 (30.6) | 10 (29.4) | 1 (50.0) | |
| Temozolomide | 2 (18.2) | 2 (5.6) | 1 (2.9) | 1 (50.0) | |
| Ipilimumab | 0 (0.0) | 2 (5.6) | 2 (5.9) | 0 (0) | |
| Nivolumab | 1 (9.1) | 19 (52.8) | 19 (55.9) | 0 (0) | |
| Pembrolizumab | 1 (9.1) | 2 (5.6) | 2 (5.9) | 0 (0) | |
*
P-values corresponding to univariable analysis performed between absent and present TILs.
TILs: tumor infiltrating lymphocytes; nbTILs: non-brisk TILs; bTILs; brisk TILs; IQR: interquartile range; AAPI: Asian American, Pacific Islander; NOS: not otherwise specified; mm: millimeter